Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)

Archives of Pharmacal Research

Volumn 34, Issue 8, 2011, Pages 1223-1226

  Lee, Sang Hoon ^a  

^a PharmAbcine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; HUMAN MONOCLONAL ANTIBODY; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TANIBIRUMAB; TTAC 0001; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MITOGENESIS; NONHUMAN; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HAPLORHINI; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80855140942     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0821-9     Document Type: Article

References (16)

1. Blume-Jensen, P. and Hunter, T., Oncogenic kinase signalling. Nature, 411, 355-365 (2001). (Pubitemid 32467045)
2. Carmeliet, P., Angiogenesis in life, disease and medicine. Nature, 438, 932-936 (2005). (Pubitemid 43093958)
3. Chu, Q. S., Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther., 9, 263-271 (2009).
4. Ferrara, N., VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol., 11, 617-624 (2000).
5. Ferrara, N. and Gerber, H. P., The role of vascular endothelial growth factor in angiogenesis. Acta Haematol., 106, 148-156 (2001). (Pubitemid 34124153)
6. Ferrara, N. and Kerbel, R. S., Angiogenesis as a therapeutic target. Nature, 438, 967-974 (2005). (Pubitemid 43093963)
7. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1, 27-31 (1995).
8. Gerber, H. P. and Ferrara, N., Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res., 65, 671-680 (2005). (Pubitemid 40216420)
9. Hicklin, D. J. and Ellis, L. M., Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 23, 1011-1027 (2005). (Pubitemid 46202320)
10. Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., and Rudge, J. S., VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A., 99, 11393-11398 (2002). (Pubitemid 34920936)
11. Jussila, L. and Alitalo, K., Vascular growth factors and lymphangiogenesis. Physiol. Rev., 82, 673-700 (2002). (Pubitemid 34743335)
12. Karkkainen, M. J., Mäkinen, T., and Alitalo, K., Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol., 4, E2-E5 (2002). (Pubitemid 34071967)
13. Kerbel, R. S., Tumor angiogenesis: past, present and the near future. Carcinogenesis, 21, 505-515 (2000). (Pubitemid 30137936)
14. Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B., Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer, 2, 826-835 (2002). (Pubitemid 37328901)
15. Spratlin, J. L., Mulder, K. E., and Mackey, J. R., Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol., 6, 1085-1094 (2010).
16. Spratlin, J., Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep., 13, 97-102 (2011).